| Title |
Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment
|
|---|---|
| Published in |
Biologics in Therapy, February 2012
|
| DOI | 10.1007/s13554-012-0001-6 |
| Pubmed ID | |
| Authors |
Andreas Reiff |
| Abstract |
With the recent approval of tocilizumab as the first biologic for the treatment of systemic juvenile idiopathic arthritis (sJIA), an important unmet medical need for this historically challenging disease has now been met. The purpose of this review article is to revisit the established therapeutic options for sJIA, to summarize the history of the clinical trials with tocilizumab, and to discuss its role in the treatment of sJIA. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 4% |
| Unknown | 25 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 4 | 15% |
| Student > Ph. D. Student | 4 | 15% |
| Professor | 3 | 12% |
| Researcher | 3 | 12% |
| Student > Master | 3 | 12% |
| Other | 6 | 23% |
| Unknown | 3 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 54% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 12% |
| Neuroscience | 1 | 4% |
| Biochemistry, Genetics and Molecular Biology | 1 | 4% |
| Unknown | 7 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 March 2022.
All research outputs
#5,240,751
of 25,374,917 outputs
Outputs from Biologics in Therapy
#3
of 20 outputs
Outputs of similar age
#42,288
of 253,528 outputs
Outputs of similar age from Biologics in Therapy
#1
of 1 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 20 research outputs from this source. They receive a mean Attention Score of 2.6. This one scored the same or higher as 17 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 253,528 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them